Earnings Call Summary | Altimmune(ALT.US) Q1 2024 Earnings Conference
Earnings Call Summary | Altimmune(ALT.US) Q1 2024 Earnings Conference
The following is a summary of the Altimmune, Inc. (ALT) Q1 2024 Earnings Call Transcript:
以下是Altimmune, Inc.（ALT）2024年第一季度業績電話會議記錄摘要：
Financial Performance:
財務業績：
Altimmune reported cash and cash equivalents of approximately $182.1 million at Q1 2024 end.
They suffered a net loss of $24.4 million or $0.34 loss per share in Q1 2024, mostly due to increased research and development expenses.
The company saw research and development expenses rise to $21.5 million in Q1 2024 from $17.2 million in Q1 2023.
Total revenue was negligible for Q1 2024.
Altimmune報告稱，截至2024年第一季度末，現金及現金等價物約爲1.821億美元。
他們在2024年第一季度淨虧損2440萬美元，合每股虧損0.34美元，這主要是由於研發費用增加。
該公司的研發費用從2023年第一季度的1,720萬美元增至2024年第一季度的2150萬美元。
2024 年第一季度的總收入微不足道。
Business Progress:
業務進展：
The company reports steady progress towards developing an oral version of pemvidutide.
Positive body composition data from Phase 2 MOMENTUM trial, with 74.5% of weight loss being body fat in patients on pemvidutide.
They are currently enrolling for the IMPACT study, a Phase 2b trial evaluating pemvidutide in approximately 190 subjects with top line results expected in Q1 2025.
Altimmune is working towards finding a prospective partner to fully exploit the potential of their programs in obesity and MASH, among other potential applications.
The firm announced progress in creating an oral version of pemvidutide.
Altimmune is exploring additional indications for pemvidutide beyond obesity and MASH.
The company is focusing on using glucagon for obesity treatment and expects to work with a safety database of around 5,000 subjects across 3 to 4 trials.
The company reported a 21% drop in LDL in subjects, suggesting possible market differentiation.
For NASH program, they reported a good enrolment rate and are expecting program readouts in Q1 next year.
They see potential for pemvidutide in the diabetes area and are considering changes to the drug's titration for Phase 3.
該公司報告說，在開發口服版pemvidutide方面取得了穩步進展。
來自II期MOMENTIM試驗的陽性身體成分數據，服用pemvidutide的患者體內脂肪減輕的比例爲74.5％。
他們目前正在報名參加IMPACT研究，這是一項2b期試驗，評估了約190名受試者的pemvidutide，預計將在2025年第一季度獲得最高結果。
Altimmune正在努力尋找潛在的合作伙伴，以充分利用其在肥胖和MASH等潛在應用領域的潛力。
該公司宣佈在創建口頭版pemvidutide方面取得了進展。
Altimmune正在探索除肥胖和MASH之外的其他pemvidutide適應症。
該公司專注於使用胰高血糖素治療肥胖，並預計將在3至4項試驗中使用約5,000名受試者的安全數據庫。
該公司報告稱，受試者的低密度脂蛋白下降了21％，這表明市場可能存在分化。
對於NASH項目，他們報告了良好的入學率，並預計明年第一季度將有計劃讀數。
他們看到了pemvidutide在糖尿病領域的潛力，並正在考慮改變該藥物在3期的滴定值。
More details: Altimmune IR
更多詳情： Altimmune IR
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更多詳情，請訪問投資者關係網站。本文僅供投資者參考，不構成任何投資建議。
譯文內容由第三人軟體翻譯。